Hemophilia A and incidence of inhibitors

Factor VIII has always been the standard of care in the prophylactic and on demand treatment of hemophilia A. Development of inh ibitors (antibodies) against factor VIII remains the most challenging Event in this treatment. Current review of data revisits the etiology and management of such an outcome, as well as reviewing current and emerging therapeutic modalities.